Business
Physiomics Appoints New Chief Executive Officer
Physiomics Appoints New Chief Executive Officer.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 4789V Physiomics PLC 18 April 2016 \n\n \nPhysiomics plc \n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics Appoints a New Chief Executive Officer\n \n \nFurther to the announcement of 31 March 2016, the Company confirms that Dr James Simon Millen, aged 47 is to be appointed Chief Executive Officer of the Company with effect from today (18th April 2016). Dr James Millen, known also as Jim, has experience of drug development and of licensing deals in global pharma companies. The Company also confirms that Dr Mark Chadwick will step down as Chief Executive Officer today, but as previously announced will remain on the Board of Physiomics as a NED for the foreseeable future.\nJim is currently a director of LifeScience Advisors Limited, Oval Medical Technologies Limited, Opticin Limited, HBM Biocapital II Management Limited and is a partner of Treehill Advisors LLP. He is not and has not been a director or partner of any other company or partnership in the last five years.\n \nDr Millen qualified as a medical doctor at Cambridge University and London and Barts Medical School, he also holds an MBA from INSEAD. He held senior business development and commercial roles at GSK and Allergan before leaving to pursue an ambition to work for smaller lifescience companies which he has realised though a number of executive and non-executive roles in companies in the UK and beyond. He has completed an array of deals spanning licencing, acquisition, divestment, development and commercialisation, which the directors believe should serve to support the Company's efforts to build a portfolio of products. The Company will continue to be supported by its experienced Scientific Advisory Board with particular expertise in the oncology field.\n \nChairman, Paul Harper commented \"I believe Mark has done an excellent job of directing the development of the Company's core competency of modelling and simulation applied to drug development. Under his guidance, I believe the Company has become a leader in modelling and simulation with a number of global pharmaceutical companies as clients. We look forward to continuing...